{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"95"}],"units":"Participants"}],"description":"ORR is defined as the proportion of patients with a confirmed response of complete response (CR) or partial response (PR) by RECIST v1.1 as assessed by the investigator. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. Partial Response (PR), is at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter.","groups":[{"description":"Patients with HRD status unknown who received continuous dosing with rucaparib 600 mg twice a day (BID) in 28-day cycles. Patients whose tumor genome-wide LOH was not tested or not determined were considered HRD unknown.","id":"OG000","title":"HRD Unknown"},{"description":"Patients with HRD status negative who received continuous dosing with rucaparib 600 mg twice a day (BID) in 28-day cycles. Patients whose tumor had genome-wide LOH \\< 10% were considered HRD-negative.","id":"OG001","title":"HRD Negative"},{"description":"Patients with HRD status positive who received continuous dosing with rucaparib 600 mg twice a day (BID) in 28-day cycles. Patients whose tumor had genome-wide LOH ≥ 10% were considered HRD-positive.","id":"OG002","title":"HRD Positive"},{"description":"All patients","id":"OG003","title":"Overall"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent-to-treat Population (ITT) with measurable disease at Baseline - The ITT population includes all patients who received at least 1 dose of rucaparib. One patient each in the HRD negative and HRD positive groups did not have measurable disease at Baseline.","reportingStatus":"POSTED","timeFrame":"Time from first dose to date of progression, up to approximately 19 months","title":"Objective Response Rate (ORR) Per RECIST Version 1.1","type":"PRIMARY","unitOfMeasure":"Participants"}